Ralliant Corporation (NYSE:RAL) Given Consensus Rating of “Hold” by Analysts

Ralliant Corporation (NYSE:RAL) has received a consensus recommendation of “Hold” from the twelve brokerages that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and six have assigned a buy rating to the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $64.50.

A number of analysts have recently commented on RAL shares. Citigroup boosted their target price on shares of Ralliant from $51.00 to $70.00 and gave the stock a “buy” rating in a research note on Wednesday, May 13th. Morgan Stanley boosted their target price on shares of Ralliant from $45.00 to $68.00 and gave the stock an “overweight” rating in a research note on Thursday, May 14th. Truist Financial reissued a “buy” rating and set a $68.00 target price (up from $53.00) on shares of Ralliant in a research note on Wednesday, May 13th. Royal Bank Of Canada boosted their target price on shares of Ralliant from $47.00 to $64.00 and gave the stock a “sector perform” rating in a research note on Wednesday, May 13th. Finally, Vertical Research cut shares of Ralliant from a “buy” rating to a “hold” rating and set a $65.00 target price for the company. in a research note on Wednesday, May 27th.

Institutional Trading of Ralliant

Several large investors have recently bought and sold shares of the business. First Nebraska Trust Co purchased a new stake in Ralliant during the 1st quarter valued at about $435,000. Irenic Capital Management LP grew its stake in Ralliant by 424.1% during the 1st quarter. Irenic Capital Management LP now owns 1,740,218 shares of the company’s stock valued at $72,376,000 after acquiring an additional 1,408,176 shares in the last quarter. Amundi grew its stake in Ralliant by 6.2% during the 1st quarter. Amundi now owns 148,614 shares of the company’s stock valued at $6,181,000 after acquiring an additional 8,649 shares in the last quarter. California State Teachers Retirement System grew its stake in Ralliant by 23.1% during the 1st quarter. California State Teachers Retirement System now owns 130,822 shares of the company’s stock valued at $5,441,000 after acquiring an additional 24,591 shares in the last quarter. Finally, Royal Bank of Canada grew its stake in Ralliant by 175.7% during the 1st quarter. Royal Bank of Canada now owns 50,251 shares of the company’s stock valued at $2,091,000 after acquiring an additional 32,024 shares in the last quarter.

Ralliant Stock Down 0.7%

RAL stock opened at $62.25 on Friday. The stock has a market capitalization of $6.97 billion and a P/E ratio of -5.69. The firm has a 50-day simple moving average of $50.40 and a 200-day simple moving average of $49.12. The company has a quick ratio of 1.05, a current ratio of 1.61 and a debt-to-equity ratio of 0.73. Ralliant has a 52 week low of $37.27 and a 52 week high of $63.31.

Ralliant (NYSE:RAL) last released its earnings results on Tuesday, May 12th. The company reported $0.57 EPS for the quarter, topping analysts’ consensus estimates of $0.49 by $0.08. The business had revenue of $534.60 million during the quarter. Ralliant had a negative net margin of 58.55% and a positive return on equity of 12.49%. Ralliant’s quarterly revenue was up 11.0% compared to the same quarter last year. Ralliant has set its FY 2026 guidance at 2.530-2.690 EPS and its Q2 2026 guidance at 0.580-0.640 EPS. Equities analysts forecast that Ralliant will post 2.64 earnings per share for the current fiscal year.

Ralliant Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 23rd. Investors of record on Monday, June 8th will be paid a dividend of $0.05 per share. This represents a $0.20 annualized dividend and a yield of 0.3%. The ex-dividend date of this dividend is Monday, June 8th. Ralliant’s dividend payout ratio is currently -1.83%.

About Ralliant

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.